Charles T. Semelka

Charles T. Semelka

Auto-generated profile, based on publicly available information

Charles T. Semelka

Department of Medicine, Section on Geriatric Medicine and Gerontology, Wake Forest University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
CSCharles T. Semelka
Charles T. Semelka
MDMichael E. DeWitt
Michael E. DeWitt
MBMaria W. Blevins
Maria W. Blevins
BHBeth C. Holbrook
Beth C. Holbrook
JSJohn W. Sanders
John W. Sanders
MAMartha A. Alexander-Miller
Martha A. Alexander-Miller
Background: Immune responses to COVID-19 mRNA vaccines have not been well characterized in frail older adults. We postulated that frailty is associated with impaired antibody and cellular mRNA vaccine responses. Methods: We followed older adults in a retirement facility with longitudinal clinical and serological samples from the first Moderna mRNA-1273 vaccine dose starting in February 2021 through their 3rd (booster) vaccine dose. Outcomes were antibody titers, antibody avidity, and AIM+ T cell function and phenotype. Statistical analysis used linear regression with clustered error for antibody titers over multiple timepoints with clinical predictors including, age, sex, prior infection status, and clinical frailty scale (CFS) score. T cell function analysis used linear regression models with clinical predictors and cellular memory phenotype variables. Results: Participants (n = 15) had median age of 90 years and mild, moderate, or severe frailty scores (n = 3, 7, or 5 respectively). Over the study time course, anti-spike antibody titers were 10-fold higher in individuals with lower frailty status (p = 0.001 and p = 0.005, unadjusted and adjusted for prior COVID-19 infection). Following the booster, titers to spike protein improved regardless of COVID-19 infection or degree of frailty (p = 0.82 and p = 0.29, respectively). Antibody avidity significantly declined over 6 months in all participants following 2 vaccine doses (p < 0.001), which was further impaired with higher frailty (p = 0.001). Notably, avidity increased to peak levels after the booster (p < 0.001). Overall antibody response was inversely correlated with a phenotype of immune-senescent T cells, CD8 + CD28- TEMRA cells (p = 0.036, adjusted for COVID-19 infection). Furthermore, there was increased detection of CD8 + CD28- TEMRA cells in individuals with greater frailty (p = 0.056, adjusted for COVID-19). Conclusions: We evaluated the immune responses to the Moderna COVID-19 mRNA vaccine in frail older adults in a retirement community. A higher degree of frailty was associated with diminished antibody quantity and quality. However, a booster vaccine dose at 6 months overcame these effects. Frailty was associated with an increased immune-senescence phenotype that may contribute to the observed changes in the vaccine response. While the strength of our conclusions was limited by a small cohort, these results are important for guiding further investigation of vaccine responses in frail older adults.

21 April 2022 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
CSCharles T Semelka
Charles T Semelka
MDMichael E DeWitt
Michael E DeWitt
KCKathryn E Callahan
Kathryn E Callahan
DHDavid M Herrington
David M Herrington
MAMartha A Alexander-Miller
Martha A Alexander-Miller
JSJohn W Sanders
John W Sanders
COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined. Observational study of adults aged 55 and older from 1 U.S. health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index (eFI) score from their medical record (n = 1 677). Participants’ frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models. Of 1 677 older adults with median (interquartile range) age, 67 (62 and 72) years, and frailty status (nonfrail: 879 [52%], prefrail: 678 [40%], and frail: 120 [7.2%]), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than nonfrail individuals, adjusted odds ratio (OR) 3.75, 95% confidence interval (CI; 1.04, 13.5). Seroreversion was detected in 50/1 631 individuals (3.1%) over 6 months of median follow-up antibody testing. Frail individuals were more likely to serorevert than nonfrail individuals, adjusted OR 3.02, 95% CI (1.17, 7.33). Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomplete descriptor of vaccine response, the high sensitivity of this antibody combined with health-system data reinforce our conclusions that frailty is an independent predictor of impaired antibody response to the COVID-19 mRNA vaccines. Frailty should be considered in vaccine studies and prevention strategies.

6 August 2024 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
CSCharles Semelka
Charles Semelka
VFValerie Freeman
Valerie Freeman
JWJeff Williamson
Jeff Williamson
EFErica Frechman
Erica Frechman

6 March 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CSCharles T Semelka
Charles T Semelka
DODavid A Ornelles
David A Ornelles
NONathaniel S O’cOnnell
Nathaniel S O’cOnnell
EPEmma C Parsons
Emma C Parsons
MBMaria W Blevins
Maria W Blevins
WBWerner E Bischoff
Werner E Bischoff
Understanding transmission of severe acute respiratory syndrome coronavirus 2 informs infection prevention practices. Air sampling devices were placed in patient hospital rooms for consecutive collections with and without masks. With patient mask use, no virus was detected in the room. High viral load and fewer days from symptom onset were associated with viral particulate dispersion.

6 August 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
CSCharles T. Semelka
Charles T. Semelka
BWBrian N. White
Brian N. White
KCKathryn E. Callahan
Kathryn E. Callahan
NPNicholas M. Pajewski
Nicholas M. Pajewski
Background: Post‐acute care (PAC) is designed to help older adults recover functional independence following hospitalization. Frailty is a predictor of adverse health outcomes in hospitalized older adults, but the impact on PAC remains unclear. The objective of this study was to investigate whether (1) frailty is associated with hospital discharge location and (2) the impact of frailty and discharge location on health outcomes. Methods: We conducted a retrospective cohort study from a single US‐based healthcare system from January 2021 to September 2023 of adults aged ≥ 65 years with an electronic frailty index (eFI) frailty score and hospital admission for at least 24 h. We evaluated the odds of hospital discharge location (home, home health services [HHS], and skilled nursing facility [SNF]) and health outcomes including hospital readmission and mortality, using logistic regression and Cox‐regression models adjusted for demographics and healthcare system factors. Results: A cohort of 23,407 older adult patients was included, with a mean age of 76.7 years (SD 7.7), 53% female sex, and 19% non‐White race/ethnicity. Participant frailty was categorized as 22% non‐frail, 46% pre‐frail, 23% frail, and 8% severely frail. Patients with a higher degree of frailty were more likely to discharge with PAC (SNF or HHS) compared to home, adjusted odds ratio OR [95% CI], frail: OR 1.20 [1.09–1.33]. Frailty was a risk factor for 90‐day hospital readmissions (OR 1.91 [1.67–2.20], p < 0.001) and mortality (HR 2.56 [2.10–3.13], p < 0.001) compared to non‐frail individuals. In addition, patients discharged to SNF had higher mortality (HR 5.46 [4.43–6.73], p < 0.001), but did not have increased readmissions compared to individuals discharged home without HHS. Conclusions: Frailty in older adults was a risk factor for discharge to PAC, higher mortality, and readmissions. Automated frailty assessment can be used to identify high‐risk patients, facilitating targeted interventions across the PAC continuum.

1 August 2022 in Research Square
Verified
Preprint
Open access
PDF file
CSCharles T. Semelka
Charles T. Semelka
MDMichael E. DeWitt
Michael E. DeWitt
MBMaria W. Blevins
Maria W. Blevins
BHBeth C. Holbrook
Beth C. Holbrook
JSJohn W. Sanders
John W. Sanders
MAMartha A. Alexander-Miller
Martha A. Alexander-Miller
BACKGROUND: Immune responses to COVID-19 mRNA vaccines have not been well characterized in frail older adults. We postulated that frailty is associated with impaired antibody and cellular mRNA vaccine responses.METHODS: We followed older adults in a retirement facility with longitudinal clinical and serological samples from the first Moderna mRNA-1273 vaccine dose starting in February 2021 through their 3rd (booster) vaccine dose. Outcomes were antibody titers, antibody avidity, and AIM+ T cell function and phenotype. Statistical analysis used antibody titers in linear mixed-effects linear regression with clinical predictors including, age, sex, prior infection status, and clinical frailty scale (CFS) score. T cell function analysis used clinical predictors and cellular phenotype variables in linear regression models.RESULTS: Participants (n=15) had median age of 90 years and mild, moderate, or severe frailty scores (n=3, 7, or 5 respectively). After 2 vaccine doses, anti-spike antibody titers were higher in 5-fold higher in individuals with mild frailty compared to severe frailty and 9-fold higher in individuals with prior COVID-19 infection compared to uninfected (p=0.02 and p<0.001). Following the booster, titers improved regardless of COVID-19 infection or frailty. Antibody avidity significantly declined following 2 vaccine doses regardless of frailty status, but reached maximal avidity after the booster. Spike-specific CD4+ T cell responses were modulated by frailty and terminally differentiated effector memory TEMRA cells, and spike-specific TFH cell responses were inversely correlated with age. Additionally, an immune-senescent memory T cell phenotype was correlated with frailty and functional decline.CONCLUSIONS: We described the separate influences of frailty and age on adaptive immune responses to the Moderna COVID-19 mRNA vaccine. Though overall antibody responses were robust, higher frailty diminished initial antibody quantity, and all older adults had impaired antibody avidity. Following the booster, antibody responses improved, overcoming the effects of age and frailty. CD4+ T cell responses were independently impacted by age, frailty, and burden of immune-senescence. Frailty was correlated with increased burden of immune-senescence, suggesting an immune-mediated mechanism for physiological decline.